Genetron Health Provides Update on HCCscreen™ for Liver Cancer Early Screening in China

Author's Avatar
Nov 27, 2020
Article's Main Image

Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today provided an update for HCCscreenTM, its blood-based early screening test for hepatocellular carcinoma (“HCC”), in China.